Symptomtext
3 doses of menquadfi were administered to patients post-excursion with no reported adverse event; 3 doses of menquadfi were administered to patients post-excursion with no reported adverse event; Initial information received on 14-Apr-2023 regarding an unsolicited non-valid non-serious case received via other health professional. This case involves 3 doses of menquadfi were administered to unspecified patients post-excursion with vaccine MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [Menquadfi] with no reported adverse event. The patient's past medical history, medical treatment(s), concomitant(s) and family history were not provided. On an unknown date, the patient received suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE (formulation, strength: unknown) at dose of 3 DF (Dosage Formulation) at dose number 3 (lot U7633AA, Expiry date: 25-Apr-2025) via unknown route in unknown administration site for prophylactic vaccination (immunization). On an unknown date the patient diagnosed with a non-serious 3 doses of menquadfi were administered to patients post-excursion with no reported adverse event (poor quality product administered) (product storage error) (same day latency) following the administration of meningococcal a-c-y-w135 (t conj) vaccine. Action taken was not applicable. At time of reporting, the outcome was Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.